Identification of A-to-I RNA editing profiles and their clinical relevance in lung adenocarcinoma

• Published in: Science China. Life sciences 2022, Vol.65 (1), p.19-32
• Main Authors: Wang, Cheng, Huang, Mingtao, Chen, Congcong, Li, Yuancheng, Qin, Na, Ma, Zijian, Fan, Jingyi, Gong, Linnan, Zeng, Hui, Yang, Liu, Xu, Xianfeng, Zhou, Jun, Dai, Juncheng, Jin, Guangfu, Hu, Zhibin, Ma, Hongxia, Tan, Fengwei, Shen, Hongbing
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Adenocarcinoma of Lung - classification; Adenocarcinoma of Lung - drug therapy; Adenocarcinoma of Lung - genetics; Adenocarcinoma of Lung - pathology; Adenosine; Adenosine Deaminase - metabolism; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Biomedical and Life Sciences; Cancer; Carcinogenesis - genetics; Cell Line, Tumor - drug effects; Chemotherapy; Cohort Studies; Datasets as Topic; Deoxyribonucleic acid; DNA; DNA methylation; Editing; Gene Expression; Humans; Inhibitory Concentration 50; Life Sciences; Lung cancer; Lung Neoplasms - classification; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Mutation; Patients; Post-transcription; Prognosis; Research Paper; RNA Editing; RNA-Binding Proteins - metabolism; ROC Curve; Tumorigenesis
• ISSN: 1674-7305; 1869-1889
• DOI: 10.1007/s11427-020-1928-0

Adenosine-to-inosine (A-to-I) RNA editing is a widespread posttranscriptional modification that has been shown to play an important role in tumorigenesis. Here, we evaluated a total of 19,316 RNA editing sites in the tissues of 80 lung adenocarcinoma (LUAD) patients from our Nanjing Lung Cancer Cohort (NJLCC) and 486 LUAD patients from the TCGA database. The global RNA editing level was significantly increased in tumor tissues and was highly heterogeneous across patients. The high RNA editing level in tumors was attributed to both RNA ( ADAR1 expression) and DNA alterations (mutation load). Consensus clustering on RNA editing sites revealed a new molecular subtype (EC3) that was associated with the poorest prognosis of LUAD patients. Importantly, the new classification was independent of classic molecular subtypes based on gene expression or DNA methylation. We further proposed a simplified model including eight RNA editing sites to accurately distinguish the EC3 subtype in our patients. The model was further validated in the TCGA dataset and had an area under the curve (AUC) of the receiver operating characteristic curve of 0.93 (95%CI: 0.91–0.95). In addition, we found that LUAD cell lines with the EC3 subtype were sensitive to four chemotherapy drugs. These findings highlighted the importance of RNA editing events in the tumorigenesis of LUAD and provided insight into the application of RNA editing in the molecular subtyping and clinical treatment of cancer.